This recommendation was based on multiple clinical studies indicating that CDKN2A/B homozygous deletion is a strong adverse prognostic factor, as this genetic alteration renders IDH-mutant astrocytoma ~50% (61 v. Here, CDKN2A is linked to astrocytoma (excluding glioblastoma).